Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-015675
Filing Date
2020-03-03
Accepted
2020-03-03 19:07:23
Documents
1
Period of Report
2020-02-28

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 17471
  Complete submission text file 0001209191-20-015675.txt   19646
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-39231 | Film No.: 20684905

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39231 | Film No.: 20684904

Mailing Address TWO COMMERCE SQUARE 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA 19103
Business Address TWO COMMERCE SQUARE 2001 MARKET STREET, 28TH FLOOR PHILADELPHIA PA 19103 2678660312
Passage BIO, Inc. (Issuer) CIK: 0001787297 (see all company filings)

EIN.: 822729751 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)